Publications by authors named "Rana Rezaei"
Objectives/background: Narcolepsy type 1 (NT1) is an immune-mediated disorder characterized by excessive daytime sleepiness, cataplexy, low levels of hypocretin-1 in the cerebrospinal fluid, and a strong association with the HLA DQB1*06:02 allele. There is evidence for streptococcal infections as one pathogenic factor that may lead to NT1 as part of a multifactorial pathogenesis. Elevated titers of Antistreptolysin-O antibodies and increased inflammatory activity in response to streptococci antigens have been described in patients with NT1.
View Article and Find Full Text PDFArticle Synopsis
- Narcolepsy typically starts in childhood, but there are limited medication options for young patients; Pitolisant, approved for adults, shows potential benefits for children and adolescents with narcolepsy.
- A study involving 55 patients aged 6-18 from three European centers assessed the effects of Pitolisant on symptoms, finding significant reductions in excessive daytime sleepiness and cataplexy frequency.
- The treatment was generally well-tolerated, with mild side effects, primarily short-term insomnia, indicating that Pitolisant could be a promising option for managing narcolepsy in younger patients.
The main objective of this study is to evaluate the quality of nurses' work lives and mental health during outbreaks. We also use the General Health Questionnaire-28 and Walton's QWL technique to assess the association between these two and their dimensions with demographic variables and each other. First, 165 nurses from COVID-19 medical centers in Iran filled surveys for this research.
View Article and Find Full Text PDF